Inovio Pharmaceuticals Inc
INO2.255USD
-0.035-1.53%
Fechamento 11/06, 16:00（ET）Cotações atrasadas em 15 min
82.80MValor de mercado
PerdaP/L TTM
Mais detalhes de Inovio Pharmaceuticals Inc Empresa
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Informações de Inovio Pharmaceuticals Inc
Código da empresaINO
Nome da EmpresaInovio Pharmaceuticals Inc
Data de listagemDec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
Número de funcionários134
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 08
Endereço660 W. Germantown Pike
CidadePLYMOUTH MEETING
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal19462
Telefone18584103134
Sitehttps://www.inovio.com/
Código da empresaINO
Data de listagemDec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
Executivos da empresa Inovio Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Detalhamento da receita
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
3.78%
Deep Track Capital LP
3.73%
BofA Global Research (US)
2.39%
BlackRock Institutional Trust Company, N.A.
0.98%
Geode Capital Management, L.L.C.
0.82%
Outro
88.30%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
3.78%
Deep Track Capital LP
3.73%
BofA Global Research (US)
2.39%
BlackRock Institutional Trust Company, N.A.
0.98%
Geode Capital Management, L.L.C.
0.82%
Outro
88.30%
Tipos de investidores
Investidores
Proporção
Hedge Fund
6.74%
Investment Advisor
6.45%
Research Firm
3.31%
Investment Advisor/Hedge Fund
2.19%
Individual Investor
0.54%
Bank and Trust
0.26%
Venture Capital
0.04%
Outro
80.47%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
280
10.09M
18.99%
-5.77M
2025Q2
303
13.60M
26.69%
-1.85M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
2.01M
3.78%
-19.82K
-0.98%
Jun 30, 2025
Deep Track Capital LP
1.98M
3.73%
-1.14M
-36.48%
Jun 30, 2025
BofA Global Research (US)
1.27M
2.39%
-34.38K
-2.63%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
519.03K
0.98%
-1.63M
-75.88%
Jun 30, 2025
Geode Capital Management, L.L.C.
437.55K
0.82%
-409.25K
-48.33%
Jun 30, 2025
Millennium Management LLC
346.87K
0.65%
+346.87K
--
Jun 30, 2025
Renaissance Technologies LLC
328.13K
0.62%
+282.30K
+616.00%
Jun 30, 2025
Northern Trust Investments, Inc.
254.38K
0.48%
-207.32K
-44.90%
Jun 30, 2025
Morgan Stanley & Co. LLC
248.95K
0.47%
+140.66K
+129.90%
Jun 30, 2025
Cubist Systematic Strategies, LLC
171.56K
0.32%
+171.56K
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 12 horas
Atualizado em: há 12 horas
Nome
Proporção
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
DFA Dimensional US Core Equity Market ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
iShares Russell 3000 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Data
Tipo
Proporção
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
